The technological advances in high‐throughput screening have led to a rapid increase in the understanding of genetic interaction profiles and the ability to identify novel SL drug targets.[42] Given our previous data showing sgRNAs directed against STAG2 conferred ATM inhibitor sensitivity,[4] we further determined whether tumor cells with STAG2 depletion were susceptible to ATM inhibition. This evidence concerns the gene ATM and neoplasm.